Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BULLETIN
December 22, 2003
- BUSINESS NEWS IN BRIEF
December 22, 2003
- Segami Medics Aims for \100 Bil. Sales as Early as Possible
December 22, 2003
- Payers Clash with Healthcare Providers on Medical Fee Revision
December 22, 2003
- OTC NEWS IN BRIEF
December 22, 2003
- 4th Proposal on Special Structural Reform Zones Finalized
December 22, 2003
- MEDICAL DEVICE NEWS IN BRIEF
December 22, 2003
- REGULATORY NEWS IN BRIEF
December 22, 2003
- Malzen to Merge with Shinyakudo in May 2004
December 22, 2003
- Korosho Calls For Measures to Prevent Medical Accidents
December 22, 2003
- Pfizer Japan Reaches "Critical Mass": Mr. Bootes
December 22, 2003
- Report on Measures to Prevent Medical Accidents Compiled by JMA
December 22, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 22, 2003
- Semi-annual Business Results
December 22, 2003
- CORPORATE ROUNDUP NEWS IN BRIEF
December 22, 2003
- NEW PRODUCTS
December 22, 2003
- Virtual Heart Should Improve Drug Development Success Rates: Dr Noble
December 22, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
December 22, 2003
- Sankyo Wishes to Obtain 75% Statin Share: President Shoda
December 22, 2003
- Sales of In Vitro Diagnostics Rose 1.5% in FY2002: JACR
December 22, 2003
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…